Another preclinical study found an enhanced accumulation of the PET tracer, 64Cu-DOTA-ipilimumab in the CTLA4-expressing non-small cell lung cancer (NSCLC) tissues [88]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.